Información del artículo
Resumen
Está ampliamente aceptado que la resonancia magnética (RM) es la técnica paraclínica más relevante, no solo para establecer un diagnóstico preciso y precoz de la esclerosis múltiple (EM), sino también para predecir su pronóstico y para controlar y predecir la eficacia de los diferentes tratamientos modificadores de la enfermedad. En los últimos años se han descrito nuevos hallazgos radiológicos en la EM, y han aparecido nuevas evidencias sobre el papel de la RM en el seguimiento de la enfermedad. Asimismo, la normativa establecida por la Comisión Europea en relación con el uso de medios de contraste que contienen gadolinio ha obligado a revisar y restringir la indicación de su uso en la práctica clínica. Los radiólogos debemos estar familiarizados con estas novedades y recomendaciones para de esta manera utilizar de forma adecuada la RM en los procesos de diagnóstico y seguimiento de la EM.
Palabras clave:
Esclerosis múltiple
Resonancia magnética
Diagnóstico
Gadolinio
Guía de práctica clínica
Abstract
Magnetic resonance imaging (MRI) is widely considered to be the most important paraclinical technique for establishing an accurate early diagnosis of multiple sclerosis as well as for predicting its prognosis and monitoring and predicting the efficacy of different treatments for this disease. In recent years, new imaging findings for multiple sclerosis have been described, and new evidence about the role of MRI in the follow-up of this disease has accumulated. Moreover, the European Commission's regulations of the use of gadolinium-based contrast agents have required that the indications for their use in clinical practice be revised and restricted. Radiologists need to be familiar with these developments and recommendations to use MRI appropriately in the diagnosis and follow-up of multiple sclerosis.
Keywords:
Multiple sclerosis
Magnetic resonance imaging
Diagnosis
Gadolinium
Clinical practice guidelines
Artículo
Opciones para acceder a los textos completos de la publicación Radiología
Suscriptor
Comprar
Contactar
Teléfono para suscripciones e incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
E-mail
Bibliografía
[1]
M.P. Wattjes, À. Rovira, D. Miller, T.A. Yousry, M.P. Sormani, M.P. de Stefano, et al.
Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.
Nat Rev Neurol., 11 (2015), pp. 597-606
[2]
A. Rovira, F. Barkhof.
Multiple sclerosis and variants. En: Barkhof F, Jager R, Thurnher M, RoviraCañellas A, eds.
Clinical Neuroradiology, Cham: Springer, (2018), pp. 1-41
[3]
A. Thompson, B. Banwell, F. Barkhof, W.M. Carroll, T. Coetzee, G. Comi, et al.
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
Lancet Neurol., 17 (2018), pp. 162-173
[4]
M. Tintore, A. Vidal-Jordana, J. Sastre-Garriga.
Treatment of multiple sclerosis- success from bench to bedside.
Nat Rev Neurol., 15 (2019), pp. 53-58
[5]
M. Filippi, M.A. Rocca, M. Calabrese, M.P. Sormani, F. Rinaldi, P. Perini, et al.
Intracortical lesions: relevance for new MRI diagnostic criteria for multiple sclerosis.
Neurology., 75 (2010), pp. 1988-1994
[6]
P. Preziosa, M.A. Rocca, S. Mesaros, A. Meani, X. Montalban, J. Drulovic, et al.
Diagnosis of multiple sclerosis: a multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria.
J Neurol Neurosurg Psychiatry., 89 (2018), pp. 316-318
[7]
M. Absinta, M.A. Rocca, B. Colombo, M. Copetti, D. De Feo, A. Falini, et al.
Patients with migraine do not have MRI-visible cortical lesions.
J Neurol., 259 (2012), pp. 2695-2698
[8]
M. Calabrese, M.S. Oh, A. Favaretto, F. Rinaldi, V. Poretto, S. Alessio, et al.
No MRI evidence of cortical lesions in neuromyelitis optica.
Neurology., 79 (2012), pp. 1671-1676
[9]
L. Cacciaguerra, A. Meani, S. Mesaros, M. Radaelli, J. Palace, I. Dujmovic-Basuroski, et al.
Brain and cord imaging features in neuromyelitis optica spectrum disorders.
Ann Neurol., 85 (2019), pp. 371-384
[10]
Calabrese M, M. Castellaro.
Cortical Gray Matter MR Imaging in Multiple Sclerosis.
Neuroimaging Clin N Am., 27 (2017), pp. 301-312
[11]
Calabrese M, M. Filippi, P. Gallo.
Cortical lesions in multiple sclerosis.
Nat Rev Neurol., 6 (2010), pp. 438-444
[12]
J.J. Geurts, S.D. Roosendaal, M. Calabrese, O. Ciccarelli, F. Agosta, D.T. Chard, et al.
Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI.
Neurology., 76 (2011), pp. 418-424
[13]
V. Sethi, T.A. Yousry, N. Muhlert, M. Ron, X. Golay, C. Wheeler-Kingshott, et al.
Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI.
J Neurol Neurosurg Psychiatry., 83 (2012), pp. 877-882
[14]
F. Nelson, A. Poonawalla, P. Hou, J.S. Wolinsky, P.A. Narayana.
3D MPRAGE improves classification of cortical lesions in multiple sclerosis.
Mult Scler., 14 (2008), pp. 1214-1219
[15]
B. Simon, S. Schmidt, C. Lukas, J. Gieseke, F. Träber, D.L. Knol, et al.
Improved in vivo detection of cortical lesions in multiple sclerosis using double inversion recovery MR imaging at 3 Tesla.
Eur Radiol., 20 (2010), pp. 1675-1683
[16]
V. Wiggermann, E. Hernández-Torres, A. Traboulsee, D.K. Li, A. Rauscher.
FLAIR2: A Combination of FLAIR and T2 for Improved MS Lesion Detection.
AJNR Am J Neuroradiol., 37 (2016), pp. 259-265
[17]
Favaretto A, D. Poggiali, A. Lazzarotto, G. Rolma, F. Causin, P. Gallo.
The Parallel Analysis of Phase Sensitive Inversion Recovery (PSIR) and Double Inversion Recovery (DIR) Images Significantly Improves the Detection of Cortical Lesions in Multiple Sclerosis (MS) since Clinical Onset.
PLoS One., 10 (2015), pp. e0127805
[18]
C. Elliott, J.S. Wolinsky, S.L. Hauser, L. Kappos, F. Barkhof, C. Bernasconi, et al.
Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions.
Mult Scler., 25 (2019), pp. 1915-1925
[19]
J.M. Frischer, S.D. Weigand, Y. Guo, N. Kale, J.E. Parisi, I. Pirko, et al.
Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque.
Ann Neurol., 78 (2015), pp. 710-721
[20]
T. Kuhlmann, S. Ludwin, A. Prat, J. Antel, W. Bruck, H. Lassmann.
An updated histological classification system for multiple sclerosis lesions.
Acta Neuropathol., 133 (2017), pp. 13-24
[21]
S. Luchetti, N.L. Fransen, C.G. van Eden, V. Ramaglia, M. Mason, I. Huitinga.
Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis.
Acta Neuropathol., 135 (2018), pp. 511-528
[22]
T. Sinnecker, J. Dorr, C.F. Pfueller, L. Harms, K. Ruprecht, S. Jarius, et al.
Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis.
Neurology., 79 (2012), pp. 708-714
[23]
S. Chawla, I. Kister, J. Wuerfel, J.C. Brisset, S. Liu, T. Sinnecker, et al.
Iron and non-iron-related characteristics of multiple sclerosis and neuromyelitis optica lesions at 7T MRI.
AJNR Am J Neuroradiol., 37 (2016), pp. 1223-1230
[24]
I.D. Kilsdonk, M.P. Wattjes, A. Lopez-Soriano, J.P. Kuijer, M.C. de Jong, W.L. de Graaf, et al.
Improved differentiation between MS and vascular brain lesions using FLAIR* at 7 Tesla.
Eur Radiol, 24 (2014), pp. 841-849
[25]
E.M. Haacke, Y. Xu, Y.C. Cheng, J.R. Reichenbach.
Susceptibility weighted imaging (SWI).
Magn Reson Med., 52 (2004), pp. 612-618
[26]
M. Absinta, G. Nair, M.C.G. Monaco, D. Maric, N.J. Lee, S.-K. Ha, et al.
The “central vein sign” in inflammatory demyelination: The role of fibrillar collagen type I.
Ann Neurol., 85 (2019), pp. 934-942
[27]
M. Absinta, P. Sati, F. Masuzzo, G. Nair, V. Sethi, H. Kolb, et al.
Association of Chronic Active Multiple Sclerosis Lesions with Disability In Vivo.
JAMA Neurol, 76 (2019), pp. 1474-1483
[28]
P. Maggi, M. Absinta, M. Grammatico, L. Vuolo, G. Emmi, G. Carlucci, et al.
Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies.
Ann Neurol., 83 (2018), pp. 283-294
[29]
M.A. Clarke, D. Pareto, L. Pessini-Ferreira, G. Arrambide, M. Alberich, F. Crescenzo, et al.
The value of 3T susceptibility-weighted imaging in the diagnosis of multiple sclerosis.
AJNR Am J Neuroradiol., 41 (2020), pp. 1001-1008
[30]
R. Cortese, L. Magnollay, C. Tur, K. Adel-Aziz, A. Jacob, F. De Angelis, et al.
Value of the central vein sign at 3T to differentiate MS from seropositive NMOSD.
Neurology., 90 (2018), pp. e1183-e1190
[31]
T. Sinnecker, M.A. Clarke, D. Meier, C. Enzinger, M. Calabrese, N. De Stefano, et al.
Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis.
JAMA Neurol, 76 (2019), pp. 1446-1456
[32]
P. Sati, J. Oh, R.T. Constable, N. Evangelou, C.R.G. Guttmann, R.G. Henry, E.C. Klawiter, et al.
The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative.
Nat Rev Neurol., 12 (2016), pp. 714-722
[33]
George IC, P. Sati, M. Absinta, I.C. Cortese, E.M. Sweeney, C.D. Shea, et al.
Clinical 3-tesla FLAIR* MRI improves diagnostic accuracy in multiple sclerosis.
Mult Scler., 22 (2016), pp. 1578-1586
[34]
M.A. Clarke, A.P. Samaraweera, Y. Falah, A. Pitiot, C.M. Allen, R.A. Dineen, et al.
Single Test to ARrive at Multiple Sclerosis (STAR-MS) diagnosis: A prospective pilot study assessing the accuracy of the central vein sign in predicting multiple sclerosis in cases of diagnostic uncertainty.
Mult Scler., 26 (2020), pp. 433-441
[35]
N. Mistry, R. Abdel-Fahim, A. Samaraweera, O. Mougin, E. Tallantyre, C. Tench, et al.
Imaging central veins in brain lesions with 3-T T2*-weighted magnetic resonance imaging differentiates multiple sclerosis from microangiopathic brain lesions.
Mult Scler., 22 (2016), pp. 1289-1296
[36]
R. Magliozzi, R. Reynolds, M. Calabrese.
MRI of cortical lesions and its use in studying their role in MS pathogenesis and disease course.
Brain Pathol., 28 (2018), pp. 735-742
[37]
L. Bo, C.A. Vedeler, H.I. Nyland, B.D. Trapp, S.J. Mork.
Subpial demyelination in the cerebral cortex of multiple sclerosis patients.
J Neuropathol Exp Neurol., 62 (2003), pp. 723-732
[38]
R. Zivadinov, D.P. Ramasamy, M. Vaneckova, S. Gandhi, A. Chandra, J. Hagemeier, et al.
Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study.
Mult Scler., 23 (2017), pp. 1336-1345
[39]
N. Bergsland, D. Ramasamy, E. Tavazzi, D. Hojnacki, B. Weinstock-Guttman, R. Zivadinov, et al.
Leptomeningeal Contrast Enhancement Is Related to Focal Cortical Thinning in Relapsing-Remitting Multiple Sclerosis: A Cross-Sectional MRI Study.
AJNR Am J Neuroradiol., 40 (2019), pp. 620-625
[40]
M. Absinta, D. Ontaneda.
Controversial association between leptomeningeal enhancement and demyelinated cortical lesions in multiple sclerosis.
Mult Scler., 26 (2020), pp. 135-136
[41]
M. Absinta, L. Vuolo, A. Rao, G. Nair, P. Sati, I.C.M. Cortese, et al.
Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis.
Neurology., 85 (2015), pp. 18-28
[42]
M. Absinta, I.C. Cortese, L. Vuolo, G. Nair, M.O. de Alwis, J. Ohayon, et al.
Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases.
Neurology., 88 (2017), pp. 1439-1444
[43]
J. Zurawski, H. Lassmann, R. Bakshi.
Use of Magnetic Resonance Imaging to Visualize Leptomeningeal Inflammation in Patients with Multiple Sclerosis: A Review.
JAMA Neurol., 74 (2017), pp. 100-109
[44]
R. Zivadinov, D.P. Ramasamy, J. Hagemeier, C. Kolb, N. Bergsland, F. Schweser, et al.
Evaluation of Leptomeningeal Contrast Enhancement Using Pre-and Postcontrast Subtraction 3D-FLAIR Imaging in Multiple Sclerosis.
AJNR Am J Neuroradiol., 39 (2018), pp. 642-647
[45]
Jonas SN, I. Izbudak, A.A. Frazier, D.M. Harrison.
Longitudinal Persistence of Meningeal Enhancement on Postcontrast 7T 3D-FLAIR MRI in Multiple Sclerosis.
AJNR Am J Neuroradiol., 39 (2018), pp. 1799-1805
[46]
À. Rovira.
Imaging of meningeal inflammation should become part of the routine MRI protocol - Commentary.
Mult Scler., 25 (2019), pp. 333-335
[47]
Rotstein D, X. Montalban.
Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis .Nat Rev Neurol., 15 (2019), pp. 287-300
[48]
Bose G, M.S. Freedman.
Precision medicine in the multiple sclerosis clinic: Selecting the right patient for the right treatment.
Mult Scler., 26 (2020), pp. 540-547
[49]
L.K. Fisniku, P.A. Brex, D.R. Altmann, K.A. Miszkiel, C.E. Benton, R. Lanyon, et al.
Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.
Brain., 131 (2008), pp. 808-817
[50]
Tintore M, À. Rovira, J. Río, S. Otero-Romero, G. Arrambide, C. Tur, et al.
Defining high, medium and low impact prognostic factors for developing multiple sclerosis.
Brain., 138 (2015), pp. 1863-1874
[51]
M. Tintoré, A. Rovira, G. Arrambide, R. Mitjana, J. Río, C. Auger, et al.
Brainstem lesions in clinically isolated syndromes.
Neurology., 75 (2010), pp. 1933-1938
[52]
G. Arrambide, A. Rovira, J. Sastre-Garriga, C. Tur, J. Castilló, J. Río, et al.
Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor.
Mult Scler., 24 (2018), pp. 301-312
[53]
W.J. Brownlee, D.R. Altmann, P. Alves Da Mota, J.K. Swanton, K.A. Miszkiel, C. Gandini, et al.
Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome.
Mult Scler., 23 (2017), pp. 665-674
[54]
I. Dekker, M.P. Wattjes, Brain, M.R. Spinal Cord.
Imaging Features in Multiple Sclerosis and Variants.
Neuroimaging Clin N Am., 27 (2017), pp. 205-227
[55]
K.K. Chung, D. Altmann, F. Barkhof, K. Miszkiel, P.A. Brex, J. O’Riordan, et al.
A 30-Year Clinical and Magnetic Resonance Imaging Observational Study of Multiple Sclerosis and Clinically Isolated Syndromes.
Ann Neurol., 87 (2020), pp. 63-74
[56]
M. Tintore, G. Arrambide, S. Otero-Romero, P. Carbonell-Mirabent, J. Río, C. Tur, et al.
The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS.
MultScler, 15 (2019 Oct),
[57]
W.J. Brownlee, D.R. Altmann, F. Prados, K.A. Miszkiel, A. Eshaghi, C.A.M. Gandini -Wheeler-Kingshott, et al.
Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis.
Brain., 142 (2019), pp. 2276-2287
[58]
A. Scalfari, C. Romualdi, R.S. Nicholas, M. Mattoscio, R. Magliozzi, A. Morra, et al.
The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis.
Neurology., 90 (2018), pp. e2107-e2118
[59]
D.T. Okuda, E.M. Mowry, B.A. Cree, E.C. Crabtree, D.S. Goodin, E. Waubant, et al.
Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome.
Neurology., 76 (2011), pp. 686-692
[60]
Okuda DT, A. Siva, O. Kantarci, M. Inglese, I. Katz, M. Tutuncu, et al.
Radiologically isolated syndrome: 5-year risk for an initial clinical event.
PLoS One., 9 (2014), pp. e90509
[61]
J. Sastre-Garriga, D. Pareto, M. Battaglini, M.A. Rocca, O. Ciccarelli, C. Enzinger, et al.
MAGNIMS consensus guidelines on the use of brain and spinal cord atrophy measures in clinical practice.
Nat Rev Neurol., 16 (2020), pp. 171-182
[62]
T. Kanda, T. Fukusato, M. Matsuda, K. Toyoda, H. Oba, J. Kotoku, et al.
Gadolinium-based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction: Evaluation of Autopsy Brain Specimens with Inductively Coupled Plasma Mass-Spectroscopy-.
Radiology., 276 (2015), pp. 228-232
[63]
T. Kanda, K. Ishii, H. Kawaguchi, K. Kitajima, E. Takenaka.
High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: Relationship with increasing cumulative dose of a gadolinium based contrast material.
Radiology., 270 (2014), pp. 834-841
[64]
I.A. Dekkers, R. Roos, A.J. van der Molen.
Gadolinium retention after administration of contrast agents based on linear chelators and the recommendations of the European Medicines Agency.
Eur Radiol., 28 (2018), pp. 1579-1584
[65]
M.P. Sormani, N. De Stefano.
Defining and scoring response to IFN-β in multiple sclerosis.
Nat Rev Neurol., 9 (2013), pp. 504-512
[66]
Rovira A, C. Auger, J. Alonso.
Magnetic resonance monitoring of lesion evolution in multiple sclerosis.
Ther Adv Neurol Disord., 6 (2013), pp. 298-310
[67]
Cotton F, H.L. Weiner, F.A. Jolesz, C.R. Guttmann.
MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals.
Neurology., 60 (2003), pp. 640-646
[68]
J. Río, J. Castilló, A. Rovira, M. Tintoré, J. Sastre-Garriga, A. Horga, et al.
Measures in the first year of therapy predict the response to interferon beta in MS.
Mult Scler., 15 (2009), pp. 848-853
[69]
J. Río, A. Rovira, M. Tintoré, J. Sastre-Garriga, J. Castilló, C. Auger, et al.
Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients.
Mul tScler., 20 (2014), pp. 1602-1608
[70]
J.R. Berger.
Classifying PML risk with disease modifying therapies.Mult Scler Relat Disord., 12 (2017), pp. 59-63
[71]
E.O. Major, T.A. Yousry, D.B. Clifford.
Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned.
Lancet Neurol., 17 (2018), pp. 467-480
[72]
Z. Novak, A.S. Thurmond, P.L. Ross, M.K. Jones, K.L. Thornburg, R.W. Katzberg.
Gadolinium-DTPA transplacental transfer and distribution in fetal tissue in rabbits.
Invest Radiol., 28 (1993), pp. 828-830
[73]
J.G. Ray, M.J. Vermeulen, A. Bharatha, W.J. Montanera, A.L. Park.
Association Between MRI Exposure During Pregnancy and Fetal and Childhood Outcomes.
JAMA., 316 (2016), pp. 952-961
[74]
C.A. Barrera, M.L. Francavilla, S.D. Serai, J.C. Edgar, C. Jaimes, M.S. Gee, et al.
Specific Absorption Rate and Specific Energy Dose: Comparison of 1.5-T versus 3.0-T Fetal MRI.
Radiology., 295 (2020), pp. 664-674
[75]
C.D. Chambers, K.A. Johnson, L.M. Dick, R.J. Felix, K.L. Jones.
Maternal fever and birth outcome: a prospective study.
Teratology., 58 (1998), pp. 251-257
[76]
M.E. Moretti, B. Bar-Oz, S. Fried, G. Koren.
Maternal hyperthermia and the risk for neural tube defects in offspring: systematic review and meta-analysis.
Epidemiology., 16 (2005), pp. 216-219
[77]
ESUR Guidelines on Contrast Agents. European Society of Urogenital Radiology. V10. March 2018. http://www.esur.org/fileadmin/content/2019/ESUR_Guidelines_10.0_Final_Version.pdf Consultado 23 marzo 2020.
